While our investigation focuses on the absence of CB1 in mice without pre-existing liver diseases, other studies assess the effects of CB1 antagonists in animal models with established liver pathologies (Liu et al., 2019; Mboumba Bouassa et al., 2022; Tam et al., 2011). Here, CNR1 is linked to liver disorder.